Felbamate

Summary

Felbamate (CHEMBL1094) is an approved small-molecule anticonvulsant (ATC N03AX10); indicated across 4 conditions including epilepsy and visual epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AX10
• Indications: 4 conditions
• Clinical trials: 2
• Chemistry: 238.24 Da · C11H14N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1094
Name	Felbamate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3331
ChEBI	CHEBI:4995
ATC	N03AX10
Molecular formula	C11H14N2O4
Molecular weight	238.24
InChIKey	WKGXYQFOCVYPAC-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N

IUPAC name: (3-carbamoyloxy-2-phenylpropyl) carbamate

ChEBI definition: The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.

Pharmacological roles (ChEBI): anticonvulsant, neuroprotective agent.

Also known as: ADD-03055, Felbamate, Felbamato, Felbatol, NSC-759866, Taloxa, W-554, SID11113343, SID50104096, SID855835, felbamate, FELBAMATE

Parent form; salt/anhydrous children: CHEMBL2130858

Patent coverage: 2,561 distinct patent families (10,652 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Pyruvate kinase PKM, Survival motor neuron protein, Muscarinic acetylcholine receptor M1, Cytochrome P450 2D6, Cytochrome P450 1A2, Neuropeptide S receptor.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 8 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PKM	8	Potency	10	nM	CHEMBL_ACT_4388231
PKM	8	Potency	10	nM	CHEMBL_ACT_4583894
SMN1	7.4	Potency	39.8	nM	CHEMBL_ACT_3903495
P08482	6.5	Potency	316.2	nM	CHEMBL_ACT_4807497
NPSR1	6.1	Potency	794.3	nM	CHEMBL_ACT_4889105
CYP2D6	6.1	Potency	794.3	nM	CHEMBL_ACT_4998370
CYP2D6	6.1	AC50	794.3	nM	CHEMBL_ACT_6050119

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474
visual epilepsy	4	MONDO:0001386	HP:0001250
anemia	4	MONDO:0002280	MONDO:0002280

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
bipolar disorder	2	MONDO:0004985	MONDO:0004985

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00034229	PHASE2	COMPLETED	Clinical Trial of Felbamate for Treatment-Resistant Bipolar Depression
NCT03196466	Not specified	COMPLETED	Population Pharmacokinetics of Antiepileptic in Pediatrics

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).